Cybin (CYBN) said Monday that data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.
By 12 months, response rates for two 16-milligram doses of the drug given three weeks apart were 100% while 71% of the eight study participants were in remission, the company said.
Cybin said it recently initiated a phase 3 trial to evaluate CYB003's effectiveness and safety in a larger number of patients. The drug earlier received Breakthrough Therapy Designation from the US Food and Drug Administration for major depressive disorder, Cybin added.
The company also said it expects to report phase 2 results for CYB004 as a potential treatment for generalized anxiety disorder in Q1.
Cybin shares were up 11% in recent premarket activity.
Price: 12.89, Change: +1.29, Percent Change: +11.12
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。